Q2 2019 13F Holders as of 6/30/2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
21.5M
-
Number of holders
-
190
-
Total 13F shares, excl. options
-
17.6M
-
Shares change
-
+216K
-
Total reported value, excl. options
-
$1.49B
-
Value change
-
+$13.1M
-
Put/Call ratio
-
2.68
-
Number of buys
-
104
-
Number of sells
-
-77
-
Price
-
$84.38
Significant Holders of ENANTA PHARMACEUTICALS INC - Common Stock (ENTA) as of Q2 2019
230 filings reported holding ENTA - ENANTA PHARMACEUTICALS INC - Common Stock as of Q2 2019.
ENANTA PHARMACEUTICALS INC - Common Stock (ENTA) has 190 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 17.6M shares
of 21.5M outstanding shares and own 82.21% of the company stock.
Largest 10 shareholders include BlackRock Inc. (2.59M shares), VANGUARD GROUP INC (1.62M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.53M shares), FARALLON CAPITAL MANAGEMENT LLC (960K shares), JANUS HENDERSON GROUP PLC (945K shares), STATE STREET CORP (860K shares), DIMENSIONAL FUND ADVISORS LP (626K shares), FIRST MANHATTAN CO (618K shares), AMERIPRISE FINANCIAL INC (578K shares), and RENAISSANCE TECHNOLOGIES LLC (550K shares).
This table shows the top 190 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.